Pushing to Improve Immunotherapies, Arcellx Raises $85 Million in Series B

Gaithersburg, Maryland-based Arcellx closed on an oversubscribed $85 million Series B financing. New investors Aju IB and Quan Capital co-led the round, joined by Mirae Asset Venture Investment, Mirae Asset Capital, LG Technology Ventures, JVC Investment Partners and funds managed by Clough Capital Partners. The financing also included existing investors Novo Holdings, SR One Limited, NEA and Takeda Ventures.